Chemically-Modified Peptides Targeting the PDZ Domain of GIPC as a

Addition, Retraction, Correction pubs.acs.org/acschemicalbiology

Chemically-Modified Peptides Targeting the PDZ Domain of GIPC as a Therapeutic Approach for Cancer Chitta Ranjan Patra,* Chamila N. Rupasinghe, Shamit K. Dutta, Santanu Bhattacharya, Enfeng Wang, Mark R. Spaller,* and Debabrata Mukhopadhyay* ACS Chem. Biol. 2012, 7 (4), 770−779. DOI: 10.1021/cb200536r

A

fter the publication of this work,1 an apparent error in one of the beta-actin blots (Figure 8d) was brought to our

Figure 8. (d) In vivo effect of intratumoral injection of peptides on IGF-1R expression in breast tumor model. IGF-1R expression is decreased in the harvest tumors after CR1166 treatment (T) compared to tumors treated with DMSO control (U) and CR2059.

attention. After we reviewed the original gel data, we identified the source of this mistake. It appears that in the submitted manuscript, we had accidently placed the incorrect beta-actin bands in Figure 8d during figure compilation. This has now been corrected in the new Figure 8d. The results and the interpretation of the figure have not changed and do not alter in any way the conclusion of the manuscript. We regret this unintentional error and any inconvenience this may have caused.

■

REFERENCES

(1) Patra, C. R., Rupasinghe, C. N., Bhattacharya, S., Wang, E., Spaller, M. R., and Mukhopadhyay, D. (2012) Chemically-Modified Peptides Targeting the PDZ Domain of GIPC as a Therapeutic Approach for Cancer. ACS Chem. Biol. 7 (4), 770−779.

© XXXX American Chemical Society

A

DOI: 10.1021/cb500865a ACS Chem. Biol. XXXX, XXX, XXX−XXX